Amlodipine an overview

Clinical Drug Investigation

Volumn 13, Issue SUPPL. 1, 1997, Pages 1-11

  Nayler, Winifred G ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Wabey House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CATECHOLAMINE; RENIN;

ADULT; AGE; AGED; ANGINA PECTORIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CATECHOLAMINE BLOOD LEVEL; CIRCADIAN RHYTHM; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LIVER DISEASE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; VASCULAR RESISTANCE;

EID: 0030791325     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199700131-00003     Document Type: Article

References (126)

1. Burges RA, Dodd MG. Amlodipine. Cardiovasc Drug Rev 1990; 8: 25-44
2. Burges RA, Moisey D. Unique pharmacologic properties of amlodipine. Am J Cardiol 1994; 73: 2-9A
3. Nayler WG. Amlodipine. Berlin: Springer-Verlag, 1993: 1-241
4. Catterall WA, Seagar MJ, Takahashi M, et al. Molecular properties of dihydropyridine-sensitive calcium channels. Ann N Y Acad Sci 1989; 560: 1-14
5. Kass R, Arena JP, Chin S. Block of L-type calcium channels by charged dihydropyridines-sensilivity to side application and calcium. J Gen Physiol 1991; 98: 63-75
6. 2+ channel blockers to the membrane lipid bi-layers. Mol Pharmacol 1992; 41: 315-21
7. Nayler WG, Gu XH. The binding of amlodipine to its receptor. J Cardiovasc Pharmacol 1992; 20 Suppl. A : S14-6
8. Coca A, Aguilera MT, Sierra A, et al. A double-blind parallel comparative study of the antihypertensive efficacy of once-daily amlodipine (AM) vs nitrendipine (NTR) with 24-hour ambulatory blood pressure (ABP) monitoring in essential hypertension (EH) [abstract 011]. Am J Hypertens 1992; 5: 109A
9. Fodor JC, Cifkova R, Gondos G, et al. Amlodipine and atenolol in the treatment of hypertension (HT) and the effect on plasma betathromboglobulin (BTG) [abstract 005]. Am J Hypertens 1992; 5: 108A
10. Hernandez R, Carvajal AR, Armas-Padilla MC, et al. The effects of once-daily amlodipine on platelet aggregation and blood pressure in patients with essential hypertension [abstract 017]. Am J Hypertens 1992; 5: 111A
11. Lund-Johansen P, Omvik P, White W, et al. Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. Postgrad Med J 1991;67 Suppl. 5: S20-4
12. Torok E, Farsang CS. Comparison of nitrendipine and amlodipine in hypertension [abstract]. Am J Hypertens 1992; 5: 110A
13. Varrone J and the Investigators of Study AML-NY-86-002. A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practise. Postgrad Med J 1991; 67 Suppl. 5: S28-31
14. Mehta JL, Lopez LM, Vlachakis NO, et al. Double-blind evaluation of the dose-relationship of amlodipine in essential hypertension. Am Heart J 1993; 125: 1704-10
15. Fowler G, Webster J, Lyons D, et al. A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension. Br J Clin Pharmacol 1993; 35: 491-8
16. Khokhani RC, Chopra P, Karnik ND, et al. Amlodipine in mild and moderate hypertension: initial Indian experience. J Assoc Phys India 1993: 41: 662-3
17. Cross BW, Kirby MG, Miller S, et al. A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension. Br J Clin Pract 1993; 47: 237-40
18. Simonetti I, Michelassi C, Gliozheni E, et al. Efficacy and tolerability of amlodipine 5mg monotherapy in mild to moderate essential hypertension. Clin Drug Invest 1997; 13 Suppl. 1: 132-6
19. Bossini A, Di Veroli C, Germano U, et al. Amlodipine vs nifedipine retard: evaluation of efficacy and tolerability using ambulatory blood pressure monitoring. Clin Drug Invest 1997; 13 Suppl. 1: 83-91
20. Franchi M, Di Perri T. A comparative study of the efficacy and tolerability of amlodipine and lisinopril in the treatment of essential hypertension. Clin Drug Invest 1997; 13 Suppl. 1: 92-6
21. Gambini C, Antonicelli R, Gesuita R, et al. Haemodynamic effects of amlodipine in elderly patients with arterial hypertension. Clin Drug Invest 1997; 13 Suppl. 1: 12-6
22. Lund-Johansen P, Omvik P, White W, et al. Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. Cardiology 1992; 80 Suppl. 1: 37-45
23. Hernandez R, Carvajal AR, Armas-de Hernandez MJ, et al. The effects of the calcium antagonist amlodipine on blood pressure and platelet aggregation in hypertensive patients. Postgrad Med J 1991; 67 Suppl. 5: S38-40
24. Mroczek WJ, Burris JF, Allenby KS. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1988; 12 Suppl. 7: S79-84
25. Leonetti G. The effects of calcium antagonists on electrolytes and water balance in hypertensive patients. J Cardiovasc Pharm 1994; 24 Suppl. A: S25-9
26. Raftery EB, Heber ME, Bridgen G, et al. 24 hour blood pressure control with the once-daily calcium antagonist amlodipine. J Cardiovasc Pharmacol 1991; 17 Suppl. 1 :S8-12
27. Lund-Johansen P, Omvik P, White W. Measurement of long-term hemodynamic changes and the use of 24-hour blood pressure monitoring to evaluate treatment. Am J Cardiol 1994; 73 (3): 44-9A
28. Osterloh I. An update on the safety of amlodipine. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S65-8
29. Adolphe AB, Vlachakis AB, Rofman RA, et al. Long-term open evaluation of amlodipine vs hydrochlorothiazide in patients with essential hypertension. Int J Clin Pharm Res 1993; 13: 203-10
30. Zanetti-Elshafer F, Pingitore R, Beretta-Piccoli C, et al. Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. Am J Hypertens 1994; 7: 36-45
31. Perondi R, Saino A, Zanchetti A, et al. Coronary vascular reactivity and calcium antagonist therapy in patients with angina. J Cardiovasc Pharmacol 1994; 24 Suppl. A: S30-6
32. Woodmansey PA, Zhang F, Channer KS, et al. Vasodilatory action of the calcium antagonist amlodipine on large and resistance pulmonary arteries from normoxic and chronically hyperoxic rats. Clin Science 1993; 85 (3): 361-6
33. Reams GP, Lau A, Hamory A, et al. Amlodipine therapy corrects renal abnormalities encountered in the hypertensive state. Am J Kidney Dis 1987; 10: 446-51
34. Dunlap ED, Matlib MA, Millard RW. Protection of regional mechanics and mitochondrial oxidative phosphorylation by amlodipine in transiently ischaemic myocardium. Am J Cardiol 1989; 64: 84-931
35. Hoff PT, Tamura Y, Lucchesi BR. Cardioprotective effects of amlodipine in the ischaemic-reperfused heart. Am J Cardiol 1989; 64: 101-161
36. Nayler WG. Amlodipine pretreatment in the ischaemic heart. Am J Cardiol 1989; 64: 65-701
37. Rämö MP, Plowden JS, Gabel M, et al. Amlodipine, a long-acting calcium antagonist drug reduces isachaemia-induced ventricular conduction delay in pig hearts. Am J Cardiol 1989; 64: 78-831
38. Gross CJ, Farber NE, Pieper GM. Effects of amlodipine on myocardial ischaemia reperfusion injury in dogs. Am J Cardiol 1989; 64: 94-1001
39. Canale C, Terrachini V, Masperone MA, et al. Open comparative study to assess the efficacy and safety of two calcium antagonists: amlodipine and diltiazem in the treatment of symptomatic myocardial ischaemia. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S57-60
40. Beckerman B, and the Investigators of Study AML-NY-87-009. An open multicenter efficacy and safety evaluation of amlodipine in the treatment of symptomatic myocardial ischaemia. Topics in Cardiovascular Medicine: 24 Hour Protection and Control, a New Era of Calcium Antagonists [symposium]. 1989 Sep 14-15: Nice
41. McGibney D. Efficacy of amlodipine in the management of ischaemic heart disease. Postgrad Med J 1991; 67 Suppl. 3: S24-8
42. Lehmann G, Reiniger G, Beyerle S, et al. Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine once-daily calcium antagonist, during acute and long term therapy of stable angina pectoris in patients pre-treated with a beta-blocker. Eur Heart J 1993; 14: 1531-5
43. Vizza CD, Sciomer S, Giustini A, et al. Efficacy of amlodipine in the treatment of stable effort angina: an echocardiographic stress study. Clin Drug Invest 1997; 13 Suppl. 1: 108-12
44. Pandolfo L, Pajes G, Zardi D, et al. Anti-ischemic efficacy of amlodipine vs nifedipine in the treatment of patients with stable exertional angina. Clin Drug Invest 1997; 13 Suppl. 1: 113-8
45. Taylor SH. Usefulness of amlodipine for angina pectoris [review]. Am J Card 1994; 73 (3): 28-33A
46. Sprint Study Group. The Secondary Prevention Reinfarction Israeli Nifedipine Trial (Sprint) II. Results. Eur Heart J 1988; 9 Suppl. 1: 350
47. Donnelly R, Meredith PA, Miller SH, et al. Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther 1993; 54: 303-10
48. Packer M, Nicod P, Khandheria BR, et al. Randomized multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure [abstract]. J Am Coll Cardiol 1991; 17 Suppl. A: 274A
49. Epstein M. Calcium antagonists and the kidney. J Cardiovasc Pharm 1994; 24 Suppl. A: S18-25
50. Kaplan NM. Amlodipine in the treatment of hypertension. Postgrad Med J 1991; 67 Suppl. 5: S15-9
51. Licata G, Scaglione R, Ganguzza A, et al. Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients. A randomised controlled study versus placebo. Eur J Clin Pharm 1993; 45: 307-11
52. Perinotto P, Ragni G, Serventi M, et al. Long-term effects of amlodipine on renal haemodynamics and microalbuminuria in patients with essential hypertension. Clin Drug Invest 1997; 13 Suppl. 1: 36-41
53. Loutzenhiser RD, Epstein M, Fischetti F, et al. Effects of amlodipine on renal hemodynamics. Am J Cardiol 1989; 64: 122-81
54. Bartlomiejczyk-Majchrowicz K, Bieniaszewski L, Rynkiewicz A. The influence of 3 months monotherapy with amlodipine on renal function, urinary albumin excretion, beta-2-microglobulin and 24 hour ambulatory blood pressure [abstract]. J Hypertens 1992; 10 Suppl. 4: 183
55. Fogari R, Zoppi A, Malamani GD, et al. Effects of amlodipine vs enalapril on microalbuminuria in hypertensive patients with type II diabetes. Clin Drug Invest 1997; 13 Suppl. 1: 42-9
56. Cappuccio FP, Markandu ND, Sagnella GA, et al. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991; 5: 115-9
57. Natochin YV, Goncharveskaya OA, Johns EJ, et al. The influence of amlodipine and verapamil on ion and water transport in the nephron, skin and urinary bladder of amphibians. Comp Biochem Physiol 1991; 98C: 317-22
58. Akpogemeh BA, Johns EJ. The characteristics of alpha-adrenoceptors mediating the renal nerve induced antinatriuresis and antidiuresis in hypertensive rats. J Hypertens 1991; 9: 373-84
59. Nayler WG. The endothelins. Berlin: Springer-Verlag, 1990: 89-106
60. Shultz P, Raij L. Effect of amlodipine on mesangial cell proliferation and protein synthesis [abstract]. Am J Hypertens 1992; 5: 14A
61. Kass R, Arena JP, Chin S. Cellular electrophysiology of amlodipine: probing the cardiac L-type calcium channel. Am J Cardiol 1989; 64: 35-421
62. Kass RS, Kwan YW. Amlodipine block of heart calcium channels: mechanisms underlying slow kinetics. J Cardiovasc Pharmacol 1992; 20 Suppl. A: S6-13
63. Hughes AD, Wijetunge S. The action of amlodipine on voltage-operated calcium channels in vascular smooth muscle. Br J Pharmacol 1993; 109: 120-5
64. Zipes DP, Besch HR, Watanabe AM. Role of the slow current in cardiac electrophysiology. Circulation 1975; 51: 761-6
65. Mitchell LB, Schroeder JS, Mason JW. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine [review]. Am J Cardiol 1982; 49: 629-35
66. Rowland E, Evans T, Krikler DM. Effect of nifedipine on atrioventricular conduction as compared with verapamil. Br Heart J 1979; 43: 124-7
67. Deedwania PC, Chaitlin MD, Das SK, et al. Amlodipine once a day in a stable angina: double-blind crossover comparison with placebo. Clin Cardiol 1993; 16: 599-602
68. Vetrovec GW, Dailey S, Kay G, et al. Haemodynamic and electrophysiological effects of amlodipine, a new long-acting calcium antagonist. Postgrad Med J 1991; 67 Suppl. 5: S60-1
69. Estrada JN, Saglietti H, Dimarco M, et al. Anti-ischaemic properties of amlodipine, a new calcium antagonist, in patients with severe coronary artery disease: a prospective trial. Postgrad Med J 1991; 67 Suppl. 5: S52-3
70. Nyrop M, Zweifler AJ. Platelet aggregation in hypertension and the effects of antihypertensive treatment. J Hypertens 1988; 6: 263-9
71. Davies MJ, Thomas AC. Thrombosis and acute coronary artery lesion in sudden cardiac ischaemic death. N Engl J Med 1984; 310: 1137-41
72. Le Quang Sang KH, Devynck MA. Increased platelet cytosolic free calcium in essential hypertension. Nouv Rev Fr Hematol 1985; 27: 279-83
73. Hernandez R, Carvajal AR, Armas-de Hermandez MJ, et al. Effects of amlodipine on platelet aggregation and blood pressure in patients with essential hypertension. Clin Ther 1993; 15: 304-13
74. Rostagno C, Colella A, Chiarantini E, et al. Effects of amlodipine on platelet aggregation in hypertensive patients: controlled ex vivo study. Clin Drug Invest 1995; 9 (5): 255-9
75. Davies MJ. Thrombosis and coronary atherosclerosis. In: Julian DG, Kubler W, Norris RM, et al., editors. Thrombolysis in cardiovascular disease. New York: Marcel Dekker, 1988: 25-43
76. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990; 335: 1109-13
77. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940-53
78. Fleckenstein-Grün G, Frey M, Thimm C, et al. Differentiation between calcium- and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists. J Cardiovasc Pharmacol 1991; 18 Suppl. 6: S1-9
79. McMurray HF, Chahwala SB. Amlodipine exerts a potent anti-migrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992; 20 Suppl. A: S54-8
80. Block LH, Bühler FR. Atherosclerosis, cell motility, calcium and calcium channel blockers. J Cardiovasc Pharmacol 1992; 19 Suppl. 2: S1-3
81. Tulenko TR. Atherogenic activity of excess membrane cholesterol in arterial smooth muscle and endothelial cells. J Am Coll Cardiol 1991; 17 Suppl. A: 24A
82. Chichester CO, Rodgers RL. Effect of doxazosin on vascular collagen synthesis, arterial pressure and serum lipids in the spontaneously hypertensive rat. J Cardiovasc Pharmacol 1987; 10 Suppl. 9: S21-6
83. Caponnetto S, Canale C, Terrachini V, et al. Open comparative study to assess the efficacy and safety of two calcium antagonists, amlodipine and diltiazem, in the treatment of symptomatic myocardial ischaemia. Postgrad Med J 1991; 67 Suppl. 5: S54-67
84. Paoletti R, Bernini F. A new generation of calcium antagonists and their role in atherosclerosis. Am J Cardiol 1990; 66: 28-31H
85. 2+ channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci 1991; 88: 9041-5
86. Tulenko IN, Mason RP, Parsons R, et al. In vitro and in vivo inhibition of arterial smooth muscle proliferation by the charged dihydropyridine amlodipine [abstract]. FASEB J 1993; 17: 269
87. Kramsch DM. Anti-atherogenic effects of amlodipine in primates [abstract]. International Society of Hypertension; 1994 March: Melbourne
88. Nayler WG. Vascular injury: mechanisms and manifestations. Am J Med 1991; 90 Suppl. 4B: 85-135
89. Nayler WG. The antiatherogenic effects of amlodipine. J Cardiovasc Pharmacol 1992; 20 Suppl. A: S51-3
90. Nayler WG. End-organ involvement and calcium antagonist therapy: animal studies. J Cardiovasc Pharmacol 1994; 24 Suppl. A: S12-7
91. Atkinson JB, Wudel JH, Hoff SJ, et al. Amlodipine reduces graft coronary heart disease in rat heterotopic cardiac allografts. J Heart Lung Transp 1993; 12 (6 Pt 1): 1036-43
92. Perloff D. Retrospective and prospective research on hypertension-related end-organ damage. J Cardiovasc Pharmcol 1994; 24 Suppl. A: S1-5
93. Mancia G, Frattola A, Parato G, et al. Blood pressure variability and organ damage. J Cardiovasc Pharm 1994; 24 Suppl. A: S6-11
94. Suzuki M, Yamanaka K, Nabata H, et al. Long term effects of amlodipine on organ damage, stroke and life span in stroke prone spontaneously hypensive rats. Eur J Pharm 1993; 228: 269-74
95. Agabiti-Rosei E, Muiesan ML, Rozzoni D, et al. Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J Cardiovasc Pharm 1994; 24 Suppl. A: S37-43
96. Cerasola G, Nardi E, Cottone S, et al. Influence of the calcium antagonist amlodipine on left ventricular mass and function in patients with essential hypertension. Clin Drug Invest 1997; 13 Suppl. 1: 17-21
97. Picca M, Peolosi GC. Effects of enalapril and amlodipine on left ventricular hypertrophy and function in hypertension [abstract]. Eur Heart J 1992; 13 Suppl.: 177
98. Picca M, Bisceglia J, Zocca A, et al. Effects of enalapril and amlodipine on left ventricular hypertrophy and function in essential hypertension. Clin Drug Invest 1997; 13 Suppl. 1: 29-35
99. Dahlöf B, Pennert K, Hansson L. Reversal of LVH in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110
100. Folkow B, Grimby G, Thulesius O. Adaptive structural changes of the vascular walls in hypertension and their relation to control of peripheral resistance. Acta Physiol Scand 1958; 44: 255-72
101. Faulkner JK, McGibney D, Chasseaud LF, et al. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 1986; 24: 713-9
102. Beresford AP, Macrae PV, Alker D, et al. Biotranformation of amlodipine. Identification and synthesis of metabolites found in rat, dog and human urine. Confirmation by gas chromatography mass spectrometry and liquid chromatography mass spectrometry. Arzneimettelforschung 1989; 39: 201-9
103. Chellingsworth M, Willis J, Jack D, et al. Pharmacokinetics and pharmacodynamics of isradipine (PN200-110) in young and elderly patients. Am J Med 1988; 85 Suppl. 3B: 72-9
104. Scott M, Castleden CM, Adam HK, et al. The effect of ageing on the disposition of nifedipine and atenolol. Br J Clin Pharmacol 1988; 25: 289-96
105. Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991; 41: 478-505
106. Abernethy DR. An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol 1994; 73 (3): 10-7A
107. Laher MS, Kelly JG, Doyle GD, et al. Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol 1988; 12 Suppl. 7: S60-3
108. Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J 1989; 118: 1100-3
109. Darnis F, Poupon R. Pharmacokinetics and safety of single oral doses of amlodipine in patients with and without hepatic impairment: an open study. Int J Clin Pharm Res 1993; 13: 29-33
110. Wollheim CB, Sharp GWG. Regulation of insulin release by calcium. Physiol Rev 1981; 61: 914-73
111. Trost BN, Weidmann P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects [review]. J Hypertens 1987; 5 Suppl. 4: 81-104
112. Seccia TM, Vulpis V, Ricci S, et al. Antihypertensive and metabolic effects of amlodipine in patients with non-insulin-dependent diabetes mellitus. Clin Drug Invest 1995; 9 (1): 16-21
113. Fogari R, Zoppi A, Mugellini, et al. Effect of benazepril plus amlodipine vs benazepril alone on urinary albumin excretion in hypertensive patients with type II diabetes and microalbuminuria. Clin Drug Invest 1997; 13 Suppl. 1: 50-5
114. Faglia E, Favales F, Quarantiello A, et al. Effect of amlodipine on insulin secretion, glucose, lipid profile and urinary albumin excretion in patients with mild hypertension and non-insulin-dependent diabetes. Clin Drug Invest 1997; 13 Suppl. 1: 56-66
115. de Courten M, Ferrari P, Schneider M, et al. Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharm 1993; 44: 457-62
116. Pessina AC, Gallucci M. Assessment of the tolerability and efficacy of amlodipine in 9295 patients with mild or moderate essential hypertension. Clin Drug Invest 1997; 13 Suppl. 1: 137-42
117. Germano G, Ramponi C, Caparra A, et al. Comparative study of the effects of amlodipine and nitrendipine on a 24-hour blood pressure profile. Clin Drug Invest 1997; 13 Suppl. 1: 77-82
118. Perna GP, De Luca G, Stanislao M, et al. Efficacy and tolerability of amlodipine in patients with stable angina pectoris: results of a multicentre study. Clin Drug Invest 1997; 13 Suppl. 1: 149-55
119. Singh S. Long-term double-blind evaluation of amlodipine and nadolol in patients with stable exertional angina pectoris. Clin Cardiol 1993; 16: 54-8
120. Silva P, Temporelli PL, Imparato A, et al. Amlodipine improves the anti-ischaemic effect of atenolol in postinfarction patients with effort-induced ischaemia: an echostress study. Clin Drug Invest 1997; 13 Suppl. 1: 22-8
121. Licciardello G, Privitera A, Calvi V, et al. Amlodipine vs nifedipine: a crossover study of efficacy and tolerability in patients with stable ansina pectoris. Clin Drug Invest 1997; 13 Suppl. 1: 119-25
122. Cahine RA, Feldman RL, Giles TD, et al. Randomised placebo-controlled trial of amlodipine in vasospastic angina. J Am Coll Cardiol 1993; 21: 1365-70
123. Casiglia E, Petucco S, Pessina AC. Antihypertensive efficacy of amlodipine and enalapril and effects on peripheral blood flow in patients with essential hypertension and intermittent claudication. Clin Drug Invest 1997; 13 Suppl. 1: 97-101
124. La Civita L, Pitaro N, Rossi M, et al. Amlodipine in the treatment of Raynaud's phenomenon: a double-blind placebo-controlled crossover study. Clin Drug Invest 1997; 13 Suppl. 1: 126-31
125. Timio M, Verdura C, Lolli S, et al. A comparative study of amlodipine and verapamil in hypertensive patients undergoing haemodialysis. Clin Drug Invest 1997; 13 Suppl. 1: 73-6
126. Perna GP, Stanislao M, De Luca G. Tolerability of amlodipine: a meta-analysis. Clin Drug Invest 1997; 13 Suppl. 1: 163-8